



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Pasotuxizumab

| | |
|-----------|---|
| Cat. No.: | HY-P99802 |
| CAS No.: | 1442657-12-6 |
| Target: | CD3 |
| Pathway: | Immunology/Inflammation |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

| | | |
|-------------------------------------|---|--|
| Description | Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with K_D s of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) ^{[1][2]} . | |
| IC₅₀ & Target | K_D s: 9.4 nM and 16.3 nM for human and cynomolgus monkey CD3. K_D s: 47.0 nM and 212.6 nM for human and cynomolgus monkey PSMA. | |
| In Vitro | Pasotuxizumab (0-100 ng/mL approximately, 48 h) leads to activation of CD4+ and CD8+ T cell populations, with EC ₅₀ s of 3.4-6.7 ng/mL for human cocultures, and 13.7-21.2 ng/mL for cynomolgus monkey cell cocultures ^[2] . Pasotuxizumab (0-100 ng/mL approximately, 48 h) increases release of interferon- γ , TNF- α , IL-2 and IL-10 in T cells ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |
| In Vivo | Pasotuxizumab (0-100 ng/mL approximately, 48 h) leads to activation of CD4+ and CD8+ T cell populations, with EC ₅₀ s of 3.4-6.7 ng/mL for human cocultures, and 13.7-21.2 ng/mL for cynomolgus monkey cell cocultures ^[2] . Pasotuxizumab (0-100 ng/mL approximately, 48 h) increases release of interferon- γ , TNF- α , IL-2 and IL-10 in T cells ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |
| | Animal Model: | PC-3-huPSMA mouse xenograft model ^[2] |
| | Dosage: | 0.005-5 mg/kg |
| | Administration: | i.v., once daily |
| | Result: | Inhibited tumor growth by 86% (0.005 mg/kg/d) and 99% (5 mg/kg/d). |
| | Animal Model: | BALB/c mice (PK Assay) ^[2] |
| | Dosage: | 0.1, 0.3, and 1 mg/kg |
| | Administration: | i.v. bolus administration or s.c. |
| | Result: | Pharmacokinetic profile of Rafivirumab. |

| Dose (mg/kg) | AUC (mg h/L) | CL _{matrix} (L/h/kg) | T _{1/2} (h) | F (%) |
|--------------|--------------|-------------------------------|----------------------|-------|
| i.v. (0.3) | 0.93 | 0.32 | 9.7 | 100 |
| s.c. (0.3) | 0.17 | | 11 | 18 |

REFERENCES

- [1]. Horst-Dieter Hummel, et al. Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). *Journal of Clinical Oncology* 2019 37:15_suppl, 5034-5034.
- [2]. Friedrich M, et al. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens. *Mol Cancer Ther.* 2012 Dec;11(12):2664-73.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA